Home/Filings/4/0001209191-21-015485
4//SEC Filing

Lewis Tanya 4

Accession 0001209191-21-015485

CIK 0001503802other

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 8:13 PM ET

Size

7.7 KB

Accession

0001209191-21-015485

Insider Transaction Report

Form 4
Period: 2021-02-25
Lewis Tanya
EVP,Chief Reg.&Quality Officer
Transactions
  • Award

    Common Stock

    2021-02-25+22,01345,401 total
  • Award

    Stock Option (right to buy)

    2021-02-25+59,96859,968 total
    Exercise: $14.56Exp: 2031-02-24Common Stock (59,968 underlying)
Footnotes (3)
  • [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.
  • [F2]The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 19,245 RSUs previously reported in Table II, and 4,143 shares of common stock.
  • [F3]This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001451038

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 8:13 PM ET
Size
7.7 KB